Platelet-derived growth factor A mRNA in platelets is associated with the degree of hepatic fibrosis in chronic hepatitis C
CONCLUSIONS: A pathway mediated by overexpression of TGFB1 via PDGFA in megakaryocytes could be involved in the development of fibrosis.
Substance misuse and needle exchange patients in Newcastle will be given “up to £25 of Greggs vouchers” if they present for a blood spot test for hepatitis C in a community pharmacy.
Authors: Ruszel N, Kubisa B, Lisowski P, Piotrowska M, Kubisa MJ, Brykczyński M, Wojtyś M, Pieróg J, Czarnecka M, Wójcik J, Wójcik N, Sielicki P, Bielewicz M, Grodzki T PMID: 31708987 [PubMed]
Should hepatitis C-infected kidneys be transplanted into uninfected recipients as standard practice? This editorial explores the issues.American Journal of Transplantation
ConclusionsGlecaprevir/pibrentasvir was highly efficacious and well tolerated in HCV treatment-na ïve patients with APRI ≤ 1 and no prior evidence of cirrhosis.Trial RegistrationClinicalTrials.gov number, NCT03212521.FundingAbbVie.Plain Language SummaryPlain language summary available for this article.
This study highlights a limited uptake of HCV treatment among MMT patients, and a need to strengthen the popularity of DOT and DAAs and integrate them into Chinese MMT clinics.
Conclusions: Vitamin D supplement did not increase SVR in treatment naïve patients with CHC irrespective of genotype. PMID: 31710801 [PubMed - as supplied by publisher]
Canadian researchers found giving uninfected recipients a combination of antiviral and cholesterol-lowering drugs prevented them from contracting the virus.
Condition: HCV Infection Interventions: Device: Optical coherence tomography angiography; Drug: Sofosbuvir (Sovaldi) Sponsor: Mohamed Saad Active, not recruiting
Human pegivirus (HPgV) is structurally similar to hepatitis C virus (HCV) and was discovered 20 years ago. Its distribution, natural history and exact rule of this viral group in human hosts remain unclear. Ou...
Liliana Chemello Direct antiviral agents (DAAs) have excellent efficacy against chronic hepatitis C virus (HCV) infection. Despite this strength, recent studies raised concerns about an unexpected hepatocellular carcinoma (HCC) occurrence rate after DAA therapy. In this exploratory case-control study, we evaluated the potential use of miRNAs as serum biomarkers for the detection of early HCC in DAA-treated patients. In the discovery phase, the circulating miRNome was assessed in 10 matched patients with (HCC+) or without HCC (HCC−) occurrence. Microarray analysis was performed before (T0) and after one month...